Table 4.
Characteristics of completed and discontinued trials. Values are numbers (percentages) unless stated otherwise
| Characteristic | Discontinued (n=81) | Completed (n=314) | Total (n=395) | P value |
|---|---|---|---|---|
| Funding: | ||||
| Non-industry | 47 (21) | 182 (79) | 229 | 0.548 |
| Industry | 34 (20) | 132 (80) | 166 | |
| Intervention: | ||||
| Operative | 12 (29) | 30 (71) | 42 | 0.251 |
| Device | 24 (23) | 82 (77) | 106 | |
| Pharmacological | 45 (18) | 202 (82) | 247 | |
| No of centres: | ||||
| Single centre | 40 (18) | 186 (82) | 226 | 0.034 |
| Multicentre | 41 (27) | 112 (73) | 153 | |
| Missing | 0 (0) | 16 (100) | 16 | |
| Sample size: | ||||
| <100 | 39 (21) | 145 (79) | 184 | 0.663 |
| ≥100 | 40 (19) | 166 (81) | 206 | |
| Missing | 2 (40) | 3 (60) | 5 | |
| Recruitment: | ||||
| National | 67 (20) | 273 (80) | 340 | 0.042 |
| International | 14 (33) | 28 (67) | 42 | |
| Missing | 0 (0) | 13 (100) | 13 | |
| Blinding: | ||||
| None | 31 (26) | 90 (74) | 121 | 0.149 |
| Single* | 14 (15) | 80 (85) | 94 | |
| Double | 35 (20) | 141 (80) | 176 | |
| Missing | 1 (25) | 3 (75) | 4 |
Percentages total across rows.
*Investigator, assessor, or patient blinding.